Diffuse large B-cell lymphoma

• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4 "Diffuse large B-cell lymphoma (DLBCL)"
• A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/ … Pending
  2024-518275-64-00 4 "Diffuse large B-cell lymphomas (DLBCL, Diffuse large B-cell "
• A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting
  2024-516869-36-00 1 2025-02-17 "Relapsed or refractory B-cell malignancies: chronic lymphocy"
• A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressi … Recruiting
  2022-502783-21-00 5 2024-02-20 "B-Cell Non-Hodgkin's Lymphoma"
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 "Diffuse Large B-Cell Lymphoma (DLBCL)"
• Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting
  2025-523297-16-00 1 2026-02-27 "Non-Hodgkin Lymphoid Malignancies (NHLs)"
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 "Diffuse large B-cell lymphoma (DLBCL)"
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 "Diffuse Large B-Cell Lymphoma (DLBCL)"
• Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non … Recruiting
  2023-506206-38-00 4 2025-04-09 "Diffuse Large B-cells non-Hodgkin Lymphoma"
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 "Diffuse Large B-Cell Lymphoma (DLBCL)"
• A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting
  2024-515034-33-00 9 2025-03-05 "Chronic Lymphocytic Leukaemia"
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly … Recruiting
  2023-505377-32-00 5 2024-08-15 "Diffuse large B-cell lymphoma (DLBCL)"
• A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CAR … Recruiting
  2024-511844-18-00 7 2024-05-02 "Relapsed or refractory CD20+ diffuse large B-cell lymphoma, "
• A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with r … Recruiting
  2022-502831-20-00 1 2024-02-15 "Male and female adult patients with relapsed Multiple Myelom"
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 "Relapsed/Refractory B-cell Malignancies"
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 "B-Cell Malignancies"
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi … Recruiting
  2022-501187-18-00 5 2023-04-24 "a. Diffuse large B-cell lymphoma (DLBCL) not otherwise speci"
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu … Recruitment ended
  2024-510965-41-00 5 2024-09-03 "Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma ("
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Recruitment ended
  2023-510178-15-00 5 2024-07-31 "High-risk Large B-cell Lymphoma"
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Recruitment ended
  2023-504028-24-00 5 2023-09-22 "Large B-Cell Lymphoma"
• A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Recruitment ended
  2023-507993-42-00 9 2022-03-17 "Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL"
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif … Recruitment ended
  2023-507286-25-00 4 2021-12-23 "Diffuse Large B-Cell Lymphoma"
• A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects … Recruitment ended
  2023-506094-35-00 3 2021-09-17 "Newly diagnosed aggressive B-cell lymphoma (a-BCL)"
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Recruitment ended
  2022-500237-92-00 5 2021-04-23 "Newly-diagnosed high-intermediate and high-risk diffuse larg"

Showing 1–24 of 47 trials